Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221188 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
A Phase 3 study of Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
- 6
- Study locations
NCT07221188 is a Phase 3 study of Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,250 participants, above the 165-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (658% higher). The trial reports 6 study locations across 3 states.
The verdict
NCT07221188, a Phase 3 study of Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efimosfermin Alfa
Study Locations (6)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Ocala
Texas
- GSK Investigational Site - San Antonio
- GSK Investigational Site - Waco
Missouri
- GSK Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2028-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221188
The ClinicalTrials.gov registry entry for NCT07221188 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 165-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (658% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07221188 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, Missouri.
Frequently Asked Questions
What is clinical trial NCT07221188 about?
NCT07221188 is a clinical study titled "A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH". This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
What is the current status of trial NCT07221188?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2025-12-12. Estimated completion is 2028-03-24.
What conditions does trial NCT07221188 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT07221188?
The interventions under investigation include: Placebo (DRUG), Efimosfermin Alfa (DRUG).
Who is sponsoring clinical trial NCT07221188?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221188 being conducted?
This trial has 6 study locations across Florida, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
ACTIVE NOT RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.